Global and Chinese trends in oligonucleotide drug clinical development: A comparative analysis
Pharmacological Research · 2024
DOI: 10.1016/j.phrs.2024.107487 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2024. Verfasst von Xiaofei Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Labo…. Hauptthemen laut MEDLINE: Drug Development, Oligonucleotides, Antisense. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Oligonucleotide drugs are anticipated to mark the new wave of pharmaceutical innovation, succeeding the eras of small molecule drugs and monoclonal antibodies. This review assessed a decade of global and Chinese clinical advancements in this field. Since 2013, there has been a notable surge in the development of oligonucleotide drugs, although a considerable majority of these candidates are still in the nascent stages of clinical trials. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) represent two pivotal classes both on global scale and within China. Rare diseases have been the main therapeutic target for oligonucleotide drugs, with a less pronounced focus in China's pipeline relative to the global trend. Concurrently, these drugs are broadening their scope to encompass a variety of indications, potentially revolutionizing treatment approaches for chronic conditions. While China's clinical development in this sector is in its infancy compared to the global stage, technological progress and favorable policies are expected to foster a new landscape of oligonucleotide drug development in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Labor…
- Shenyang Pharmaceutical University, School of Life Science and Biopharmaceuticals, Shenyang 110000, China.
Zitieren
APA
Wu, X., Liu, S., Liu, D., Li, X., Wang, H., & Han, X. (2024). Global and Chinese trends in oligonucleotide drug clinical development: A comparative analysis. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107487
Vancouver
Wu X, Liu S, Liu D, Li X, Wang H, Han X. Global and Chinese trends in oligonucleotide drug clinical development: A comparative analysis. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107487
BibTeX
@article{Wu2024,
author = {Wu, Xiaofei and Liu, Shupeng and Liu, Dan and Li, Xiuqi and Wang, Hongyun and Han, Xiaohong},
title = {Global and Chinese trends in oligonucleotide drug clinical development: A comparative analysis},
journal = {Pharmacological Research},
year = {2024},
doi = {10.1016/j.phrs.2024.107487}
}
EUVIMED